Sothema Notifies the Acquisition of Certain Assets from Eli Lilly and Company to the Competition Council

According to information provided by the parties involved, the transaction involves the purchase of assets related to medications used in the treatment of erectile dysfunction. Eli Lilly and Company, based in Indianapolis, USA, is engaged in the research, development, and production of pharmaceutical products. In accordance with regulations, the Competition Council has stated that interested third parties have a period of 10 days, until December 15, 2025, to submit any comments regarding this transaction. The publication of this notice does not prejudge the final assessment of the Council regarding the compliance of the transaction with competition rules.